Clinical Trial Update: Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial [Phase 4]

View source ↗

Summary

Phase 4 randomized trial comparing Bromfenac ophthalmic solution to Nepafenac ophthalmic suspension for ocular inflammation after cataract surgery, with extra d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation Associated with Cataract Surgery

Drugs mentioned

• ILEVRO (nepafenac)
• Prolensa (bromfenac)

Snippet

Sponsor: Silverstein Eye Centers | Conditions: Treatment of Ocular Inflammation Associated With Cataract Surgery | Phase 4 | Status: COMPLETED